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Abstract
Background: Benzodiazepines are often used on a long term basis in the elderly to treat various psychological
disorders including sleep disorders, some neurological disorders and anxiety. This is despite the risk of dependence,
cognitive impairment, and falls and fractures. Guidelines, campaigns and prescribing restrictions have been used to
raise awareness of potentially inappropriate use, however long term use of benzodiazepine and related
compounds is currently increasing in Australia and worldwide. The objective of this paper is to explore
interventions aimed at improving the prescribing and use of benzodiazepines in the last 20 years.
Methods: Medline, EMBASE, PsychINFO, IPA were searched for the period 1987 to June 2007.
Results: Thirty-two articles met the study eligibility criteria (interventions solely focusing on increasing appropriate
prescribing and reducing long term use of benzodiazepines) and were appraised. Insufficient data were presented
in these studies for systematic data aggregation and synthesis, hence critical appraisal was used to tabulate the
studies and draw empirical conclusions. Three major intervention approaches were identified; education, audit and
feedback, and alerts.
Conclusions: Studies which used a multi-faceted approach had the largest and most sustained reductions in
benzodiazepines use. It appears that support groups for patients, non-voluntary recruitment of GPs, and oral
delivery of alerts or feedback may all improve the outcomes of interventions. The choice of outcome measures,
delivery style of educational messages, and requests by GPs to stop benzodiazepines, either in a letter or face to
face, showed no differences on the success rates of the intervention.
Background
Benzodiazepines are used to treat various psychological
disorders including sleep disorders, some neurological
disorders and aspects of addiction and anxiety [1]. Utili-
zation patterns show variation in the use of benzodiaze-
pines over the last 2 decades [2,3]. During the 1990’s
there was much publicity around the harmful effects of
long-term use of benzodiazepines in Australia, including
new guidelines and efforts to increase community
awareness [4-6]. This resulted in a decrease in prescrib-
ing of benzodiazepines, however since the end of these
campaigns, use has been continually rising, with a 21%
increase in utilisation by concession beneficiaries in
Australia (elderly, over 65 years of age, and those with a
low income or receiving benefits) from 2000 to 2006 [7].
It is known that prescribers and healthcare consumers
need to be regularly reminded about reviewing long-
term/chronic treatments and what the current best
practice guidelines are [8,9]. This is especially relevant
to benzodiazepines, as Australian guidelines state that
benzodiazepines should be reserved for short term use
only, be part of a broader treatment plan, and be pre-
scribed at minimum doses [10,11]. This is due to the
risks, including dependence, cognitive impairment, and
falls and fractures [12-15]. Patients over the age of
65 years are particularly susceptible to these side effects
due to accumulation and existing frailty [16,17].
Research has shown that these restrictions are not
being implemented as the use of benzodiazepines con-
tinues to rise in Australia [7]. Whilst there have been a
* Correspondence: alesha.smith@uq.edu.au
University of Queensland, School of Pharmacy, Brisbane, Queensland, 4072,
Australia
Smith and Tett BMC Health Services Research 2010, 10:321
http://www.biomedcentral.com/1472-6963/10/321
© 2010 Smith and Tett; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.number of reviews exploring interventions to improve
prescribing or change prescribing behavior [18,19], none
have focused specifically on issues and interventions sur-
rounding benzodiazepine use. It is therefore timely that
a fresh approach is taken improve this problem.
The objective of this paper was to evaluate interven-
tions aimed at changing the use of benzodiazepines over
the last 20 years. This time period was chosen capture
the interventions implemented during the 1980 s and
1990 s when there was increased focus on improving
benzodiazepine use as well as the recent introduction of
the newer benzodiazepine-related drugs (z-drugs). This
evaluation will assist in determining a future effective
strategy designed to increase the appropriateness of
prescribing and use of benzodiazepine and related
compounds.
Methods
Study Eligibility Criteria
Studies were included if they met the inclusion criteria,
those which aimed to change benzodiazepine prescrib-
ing in any population either through education, using
outreach or by raising awareness with consumers and/or
health professionals, all study designs and locations were
included for the period 1987-June 2007.
Information Sources
A search was made of the following databases, Medline
(via Ovid), EMBASE, PsychINFO and International
Pharmaceutical Abstracts using the keywords (benzodia-
zepine(s) and anxi*) alone and in combination with
intervention strategy(ies), educat* campaign(s), health
intervention, intervention and utilis(z)ation. The search
was limited to the English language. The reference lists
of the retrieved articles and reviews were used to search
for additional articles. A citation search was conducted
and grey literature was also reviewed. The last search
was completed in June 2007.
Study Selection
The retrieved articles were screened by title (AS) any
which clearly did not include an intervention about
improving prescribing or use of benzodiazepines were
excluded. Then abstracts for the remaining articles were
scanned (AS) those studies which met the inclusion cri-
teria were retrieved after abstract examination, for full
text analysis.
Exclusion upon full text analysis was pre-determined
for the following types of studies:
(a) studies only comparing 2 or more different
dosage regimens or different ways of managing with-
drawal (i.e. after the actual decision to change use
had occurred).
(b) studies that did not distinctly report on the rates
of prescribing or use of benzodiazepines (i.e. studies
that intervened in overall psychotropic prescribing
without differentiating benzodiazepines; or those not
reporting rates of prescribing or use).
(c) studies that conducted an intervention in specific
disease populations for whom benzodiazepines may
be clinically indicated for continuous use (i.e. people
with schizophrenia, epilepsy, or opioid drug users).
(d) reviews, double publications, animal studies and
letters.
Any articles for which inclusion was uncertain were
assessed by a second author (ST) until consensus was
reached. All included studies were critically appraised
and categorized into 1 of 3 groups; educational interven-
tions, audit and feedback interventions, and alert
interventions.
Summary measures
For the purposes of this manuscript, an improvement in
the use of benzodiazepines was defined by each study’s
pre-determined criteria. The results reported are in the
same format as they were presented in the original arti-
cle, this includes results presented in Table 1, 2 and 3,
e.g. more appropriate use may be defined by the authors
as a decrease in prescribing, perhaps, or a swap to
short-acting benzodiazepine use rather than long acting
in the elderly.
Synthesis of results
Using the above summary measures, it is difficult to
quantify ‘success’ or to quantitatively compare improve-
ment between the studies due to the large variation in
design and measurement. One of the major barriers is
the definition of appropriateness of use for benzodiaze-
pines used by each different study, and therefore what is
meant by an improvement of use. This has been defined
in a number of ways; some studies used criteria, such as
Beers’ Criteria [20], others just using quantities of ben-
zodiazepines to ascertain whether recipients of benzo-
diazepines should have been receiving these medicines.
Beers’ Criteria and similar indicators are developed from
populations, and it is difficult to apply these in a over-
arching fashion, without allowing for individual clinical
need, so determining ‘appropriate/inappropriate’ based
on these rigid criteria is often controversial [21,22].
Other studies simply indicated that an ‘improvement’
was a decrease in overall use of benzodiazepines [23].
Due to the variation in reporting and the lack of statisti-
cal analysis in many studies, this review has not
included a meta analysis, instead the studies have been
tabled so that the general attributes and the design of
the studies can be compared, critiqued and discussed.
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Page 2 of 12Table 1 Educational Interventions to decrease benzodiazepine use
Study Location Intervention design:
Educational Letter Interventions Targeting Consumers
Study Design and
Size
Result Follow up
Bashir et al,
1994 [57]
London Letters sent long term users (>1 year) with a request to
visit their GP and allocated to:
1 = informed about the correct use of BZ + self help book.
2 = control (no advice)
RCT
11 GP practices 109
patients.
Sig increase in the number of patients’ that reduced BZ
prescriptions in intervention group (18%) compared to
control (5%).
6 months post
intervention
Towle and
Adams, 2006
[25]
Scotland Letter sent to repeat BZ users by pharmacist to tell them
that a step down program had been initiated and invited
them to see their GP for a medication review + repeat BZ
prescriptions were inactivated. Posters displayed in GP
practice.
Convenience Sampling
1 practice,
206 patients.
73% collected their step down program. Decreased number
of tablets prescribed by 64%. Only 23% of 369 patients
stayed on a repeat script. (No statistical analysis).
3 years (end
of the study)
Heather
et al, 2004 [26]
UK Long term BZ users (> 6 months) were allocated to:
1 = letter from GP asking them to consider cutting down
their BZs. 2 = letter inviting participants to a consultation +
leaflet and self help sleep book. 3 = control.
RCT
7 Practices, 299
patients.
Sig reduction in letter group (24%) vs. control (16%) and
sig reduction in consult (22%) vs. control (16%). No sig
difference between consultation and letter group for BZ
decrease.
6 months post
intervention
Cormack et al,
1989 [58]
UK Long term BZ users (> 1 year) were allocated to: 1 = letter
from GP advising patients to cut down BZ use. 2 =
invitation to see the GP about cutting down BZ use.
3 = control.
CT
5 practices, 75
patients.
Sig reduction in BZ use in both the letter group and the
consultation group compared to no change in control
group (data not reported).
6 months to
1 year post
intervention
Cormack et al,
1994 [23]
England Long term BZ users (> 6 months) allocated to:
1 = letter from GP to recommending stopping BZs
2 = letter from GP + monthly advice sheets.
3 = control
CT
3 practices 209
patients.
30% reduction in BZ use by intervention groups (sig
difference from control) No sig difference between
interventions.
6 months post
intervention
Gorgels et al,
2005 [59]
Netherlands 1 = discontinuation letter to long term users then
approximately 3 months after the letter, an invitation for
GP evaluation of BZ use. 2 = control.
RCT
30 practices
1707 patients
(intervention) and
1821 (control).
Sig use reduction of BZ prescriptions in intervention group
(24%) vs. control (5%). Sig reduction in BZ use in the
intervention group for those who attended the GP
evaluation (35%) vs. those who did not go (24%).
21 months
post
intervention
Morrison,
1990 [60]
UK Long term BZ users (> 6 months) were informed that they
should stop BZs by their GP. If agreed an individual plan
(how to decrease and number of follow-up visits) was
established.
Convenience Sampling
1 practice, 27/72
eligible patients
agreed.
No new long term users started during study. 37.5% quit
33.3% reduced dose by >50% and 15% remained same
dose or <50% reduction. No-one increased their dose
during the study period.
1 year (end of
study)
Onyett and
Turpin, 1988 [28]
UK Recruitment of long term users by notices. Asked to self-
reduce BZs then all participants received a pamphlet and
allocated to: 1 = group session. 2 = individual GP
appointment.
Prospective cohort
18 patients.
59% reduction in dose (group) and 69% reduction in dose
(GP meeting) but no sig difference between groups.
15 week post
intervention
Brymer and
Rusnell,
2000 [27]
Canada Home assessment by nurse to determine if patients were
substance dependent. Saw Geriatrician for medical review,
who recommended a treatment plan (also sent to their
GP). Were encouraged to join support/educational groups.
Observational study
55 elderly patients.
Significant reduction of BZ use (59%) between pre and post
intervention.
6 months post
intervention
Study Location Intervention Design:
Educational Interventions Targeting GPs
Study Design and
Size
Result Follow up
Zwar et al,
2000 [61]
Australia 1 = face to face 20 min educational visit by a GP focusing
on the management of long term users of BZs +
guidelines + leaflets on relaxation techniques for patients.
2 = control.
RCT
157 GP registrars
Sig decrease in overall BZs use in both groups (0.6 per
100 encounters for both group), however no difference
between control and intervention groups.
3 practice
surveys -
6 monthly
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2Table 1 Educational Interventions to decrease benzodiazepine use (Continued)
Smith et al,
1998
[30]
Washington,
USA
1 = mailed intervention package (guidelines, letter,
prescriber-specific profile, patient profile) for prescribers of
over users (1 tab per day >1 year)
2 = control.
RCT
GPs or pharmacist of
222 over users
Sig decrease in BZ prescribing/dose for the intervention
group (27.6%) compared to control (8.5%).
3 months post
intervention
Holm, 1990
[32]
Aarhus,
Denmark
1 = invite to a meeting on correct use of hypnotics/
sedatives + educational material given at the meeting. 2 =
mailed information on correct use and feedback on their
prescribing rate compared with others. 3 = control.
RCT
356 GPs
(245 practices)
Sig decrease (-53) in DDD/1000 pat/week between pre and
post intervention. No difference between groups 1 and 2
but sig difference between groups 2 and 3 (2 prescribed
more).
1-2 months
post
intervention
De Burgh et al,
1995 [29]
NSW,
Australia
1 = 20 min educational visit to GPs. Educational material
left (management guidelines, review cards for long term
users). Offered access to sleep aids. Recommended to
review 5 patients and received a follow-up phone call. 2 =
control.
RCT
286 GPs
An overall decrease in BZ prescribing (23.7%). No sig
difference between intervention and control for reduction
rate of BZ. Sig decrease between intervention (72%
decrease) and control (13% decrease) for rate of new BZ
scripts for insomnia.
Approx
6 months post
intervention
Midlov et al,
2006 [62]
Skane,
Sweden
1 = two educational visits from pharmacist and GP
focusing on effects of medium and long acting BZs in the
elderly. 2 = control (received intervention after the study).
RCT
15 GPs (8 in
intervention, 7 in
control)
Sig decreases in all BZ prescribing (26.63%) and 25.8%
decrease of long and medium acting BZs vs. control.
1 year post
intervention
Berings et al,
1994 [31]
East and
West
Flanders,
Belgium
1 = educational advertisement like mailings (with slogan) +
educational visit. 2 = mailings only 3 = control
RCT
128 physicians
Sig decrease for whole sample pre to post intervention. Sig
decrease in BZ prescriptions between intervention 1 (24%)
and control (3%) and intervention 2 (14%) and control and
intervention 1 and 2.
4 weeks post
intervention
Study Location Intervention Design: Educational Interventions Targeting
LTC
Study Design and
Size
Result Follow up
Hagen et al,
2005 [63]
Alberta 1 = Algorithm on non-pharmacological approaches for
agitation. Education based on algorithm to nurses,
pharmacists, or family members. 30 min education session
for GP. 2 = Control
CT
24 LTC facilities,
12 (intervention) and
12 (control)
BZ use in both the control and the intervention increased
post intervention (Sig increase for control only). At 6
months post intervention total BZ use sig higher in control
vs. intervention.
Every
2 months until
6 months post
intervention
Avorn et al,
1992 [64]
Massachusetts 1 = physicians received 3 × drug advertisement like
summaries of literature about geriatric medicine,
psychopharmacology + 3 face to face visits to each doc by
pharmacist. 4 training sessions for nurses on alternatives to
psychoactive drugs + ADRs. 2 = Control
MPR
12 LTC facilities 6
(intervention) and 6
(control) both groups
were matched
Sig difference in the % change to more appropriate BZs in
intervention (64%) vs. control (4%). E.g. long acting to short
acting.
30 days post
intervention
Schmidt et al,
1998 [65]
Sweden 1 = Monthly meeting for 12 months led by pharmacist and
included physician, and nurses. Each patient’s medications
were reviewed. 2 = Control
RCT
33 nursing homes (15
intervention,
18 control)
Sig increase (from baseline) in prescribing of appropriate
hypnotics (+70%) and anxiolytics (+ 50%) in intervention
group. No sig difference in control group
1 month post
intervention
Gilbert et al,
1993 [36]
Adelaide,
Australia
1 = letter to residents inviting participation in relaxation
groups (8 × 40 min) audio tape of relaxation for practice
and information about sleep & anxiety medications. Nurses
received a seminar on dealing with BZ withdrawal. Doctors
received letter of progress. 2 = Control
Prospective cohort
2 LTC facilities
There was a sig decrease in the % of BZs users’ from
baseline (70%) to post intervention (35%). No change in
control
12 weeks after
baseline
BZ = benzodiazepines, GP = General Practitioner, LTC = long term care, Sig = statistically significant (p < 0.05), tab = tablet, ADRs = Adverse Drug Reactions, DDD/1000 pats/week = the number of defined daily
doses dispensed per 1000 patients per week, RCT = Randomized controlled trial, CT = Controlled trial, MPR = Matched pair randomization
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2Table 2 Audit and Feedback Interventions to decrease benzodiazepine use
Study Location Intervention Design: Audit and Feedback
Interventions targeting GPs
Study Design and Size Result Follow up
Baker et al, 1997 [66] Leicester, UK Audit on all long-term users (>4 weeks) in
the medical centre then GPs received either:
1 = feedback on prescribing practices +
criteria for the management of long term
BZ users. 2 = feedback + criteria + reminder
cards for patient files.
RT
18 practices patients = 2409
long term BZ users
Both groups changed after intervention with
respect to levels of compliance to criteria.
8.2% of patients were stopped and 1.3%
were decreasing BZs. No difference between
groups.
2
nd audit completed 1 year
post intervention
Holden et al, 1994
[67]
Liverpool,
Southport - UK
Audit of BZ use + GPs invited to 2 meetings
on auditing BZ use in general practice.
Individual practices determined their own
BZ policy for prescribing and reducing use.
Observational
15 practices, 3234 patients
Overall reduction of 16%. Sig reduction in
those <65 (25%) compared to those
>65 = 12%.
2
nd audit at 8 months (end
of study)
Pimlott et al, 2003
[68]
Canada - Ontario 1 = audit and feedback on GPs prescribing
of BZs compared to peers and best
practice + information
sheet on BZs every 2 months for 6 months.
2 = Control group had the same
intervention for antihypertensives.
RCT
168 GPs (intervention) 206
GPs (control)
No sig decrease in BZ prescribing and no
sig difference between intervention and
control groups.
6 months post intervention
Study Location Intervention Design: Audit and Feedback
Targeting LTC
Study Design and Size Result Follow up
McClaugherty, 1997
[69]
Texas LTC pharmacist audited BZ use + gave
feedback to
nurses and doctors. Nurses were given sleep
promoting guidelines. OT’s & physio’s were
encouraged to increase activities for those
who couldn’t sleep.
Quasi-Experimental
10 Nursing Homes, 3 Texas
counties
% of patients prescribed routine BZ
decreased from 4.5% (baseline) to 1.6%
(post intervention). % of patients prescribed
BZ on an as needed basis increased from
7.9% (baseline) to 9.3% (post intervention)
3 months post intervention
Gill et al,
2001 [70]
Ontario, Canada Review of patients chart + a letter was sent
to the treating doctor if inappropriate e.g.
long acting BZ explaining why medication
was inappropriate and suggestions for
alternative therapy.
Quasi-Experimental
1 LTC facility, 450 Patients
37.9% of inappropriate medications were
withdrawn or changed after the letter.
2 months after follow-up
letters
Elliot et al, 2001 [37] Australia Audit and 1 h meeting = feedback to all
staff on prescribing compared to other
hospitals and review of literature + posters
in wards
Quasi-Experimental
9 hospitals (6 aged care 3
medical wards)
No sig reduction in BZ use. Sig increase in
appropriate prescribing at 8 week (22%) and
6 months (30%) post intervention.
4-8 weeks (all) and 6 months
(for 3 hospitals only) post
intervention
Study Location Intervention Design:
Audit and Feedback + Education
Targeting LTC
Study Design and Size Result Follow up
Roberts et al, 2001
[34]
QLD + NSW,
Australia
1 = 11 hrs of problem based education
session for nurses + wall charts, bulletins,
telephone, visits. Written drug review for
500 selected patients. Report on review
placed in patient’s records and available to
the GPs.
2 = Control
RCT
52 nursing homes, 13
(intervention), 39 (control).
Sig difference in the reduction of BZs
between intervention (decreased 597 items/
year/1000 residents) and control (increased
278 items/year/1000 residents).
12 months (end of study)
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2Table 2 Audit and Feedback Interventions to decrease benzodiazepine use (Continued)
Batty et al, 2001 [35] England/
Wales
Audit then:
1 = lecture to staff on literature review on
appropriate prescribing of BZs. Feedback on
prescribing compared to another hospitals.
2 = Bulletin (2 sided A4) with same
information as lecture.
3 = Control
RCT
Elderly inpatients at
17 hospitals
(6 lecture, 4 bulletin,
7 control)
No sig change in any group but verbal
group increased appropriate prescribing by
15%, bulletin decreased appropriate
prescribing (9%) and control remained the
same.
4-6 weeks post intervention
Eide and Schjott,
2001 [33]
Norway 1 = Audit of BZ use, feedback to staff
(reports and a presentation). Academic
education to all staff by pharmacist,
consisting of 6 simple rules for the use of
hypnotics (data collected in 1995 and 2000).
2 = Control (data collected in 2000 only)
CT
10 LTC Facilities,
5 (intervention) and
5 (control)
Sig dif in the % of patients use BZS in
control (44%) compared to intervention
(24%) post intervention. Sig higher dose of
BZs in intervention group in 2000 (60%)
compared to 1995 (38%).
5 years post intervention
Crotty et al, 2004
[71]
Adelaide,
Australia
Audit then:
1 = GP received education and guidelines
and audit of use. Nurses received education
in behaviour management and all staff
received education on reducing
psychotropic medication use
2 = control
MRP
20 LTC facilites,
10 (intervention) and
10 (control)
No sig reduction in BZ use (6.3%,
intervention, 0% control), no significant
decrease in long acting BZs (2.8%
intervention and 0.9% control) and no sig
difference in BZ being prescribed on a as
needed basis (4% intervention and 1%
control)
2
nd audit was at 7 months
(end of study)
BZ = benzodiazepine, GP = General Practitioner, Av = Average, Sig = statistically significant (p < 0.05), LTC = long term care, OT’s = Occupational Therapists, RCT = Randomized controlled trial, CT = Controlled trial,
RT = randomized trial, MPR = Matched pair randomisation
S
m
i
t
h
a
n
d
T
e
t
t
B
M
C
H
e
a
l
t
h
S
e
r
v
i
c
e
s
R
e
s
e
a
r
c
h
2
0
1
0
,
1
0
:
3
2
1
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
2
-
6
9
6
3
/
1
0
/
3
2
1
P
a
g
e
6
o
f
1
2It is from these critiques that factors influencing success
or otherwise can be determined, and lessons about
future study design learnt.
Risk of Bias
Some intervention studies about benzodiazepines may
have been excluded from this commentary due to the
use of the selected key words, however it was difficult to
be more general than the terms selected without gener-
ating a totally non-specific (and much larger) database
of possible articles. There may be a publication bias, as
studies are known to be less reported if they generate
negative results (or ‘no change’) with non-completion of
the intervention or write up more likely.
Results
The search of the databases returned 8437 studies
(Figure 1). Of these, 32 studies fulfilled all the pre-
determined inclusion criteria and could be categorized
as described above. For each study the data were
extracted for the following characteristics; location of
the intervention, intervention design, study type, partici-
pant numbers, intervention follow-up time and study
outcomes. Comparisons of these characteristics are
described below.
Educational Interventions
The 19 studies (summarized in Table 1) have been tar-
g e t e da t3d i f f e r e n tg r o u p s ;t h o s ea i m e da tG P s ,a tc o n -
sumers and at long term care facilities.
Audit and Feedback Interventions
The 10 studies (summarized in Table 2) were classified
into 2 categories, those aimed at GPs and those aimed
at long term care facilities. A sub category was also
identified within the interventions aimed at long term
care facilities, those which include education in addition
to audit and feedback.
Alert Interventions
These 2 studies (summarized in Table 3) were only tar-
geted at GPs.
The final study included was a multifaceted interven-
tion which used an educational approach to target GPs,
pharmacists and consumers in a rural region of South
Australia. A 19% reduction in benzodiazepine use was
maintained 2 years after the intervention finished [24].
The critiques of the 32 studies (Table 1, 2 and 3) are
discussed below.
Education
Targeted at Consumers
Consumer focused educational intervention specifically
targeted individual long term benzodiazepine users
rather than an overall public health approach or com-
munity awareness campaigns and used mail-outs as the
main approach. In all of these studies, long term benzo-
diazepine users were sent letters from a GP, or in one
case from a pharmacist [25]. The letters asked that
patients cut back on the benzodiazepines and gave basic
advice on how to do this (e.g. gradually reducing use
over a period of weeks). All of these studies saw a simi-
lar dose reduction (22% - 30%). Studies which invited
participants to visit a GP, during which consultation
they were asked to reduce their benzodiazepine dose
face to face, resulted in significant decreases in benzo-
diazepine doses compared to the control but did not
significantly differ to those who received only the letter
[23,26]. This demonstrates that a simple bulk mail-out
to identified individuals approach appears to be just as
effective in improving use of benzodiazepines, and may
have advantages compared to the more time consuming,
Table 3 Alert Interventions to decrease benzodiazepine use
Study Location Intervention Design:
Alert Interventions targeted at GPs
Study Design
and Size
Result Follow up
Simon et al,
2006 [72]
USA -
Oregon &
Washington
1 = age Specific (> 65 years) alert for
long acting BZs. 2 = alerts + academic
detailing (group education +
follow-up letter).
Cluster
randomized trial
239 clinicians
No sig decrease in prescribing to
elderly. No difference between alerts
(decrease of 3.0 dispensed medications
per 10,000 members) and alerts +
academic detailing (decrease of 19.7
dispensed medications per 10,000)
18 months
post
intervention
Monane et al,
1998 [73]
America 1 = age specific (> 65 years) alert
system at pharmacy (mail order and
retail). If medication is deemed to be
inappropriate then conversation
between pharmacist and prescriber
occurred. 2 = control.
Population based
cohort
2.3 million
people >65 years
filled a script
during study
period
Sig difference between intervention
(40% of cases) and control (2%) for the
change of prescriptions for long acting
BZs. Sig difference between control (2%)
and intervention (25%) for change to
prescriptions of short acting BZs that
exceeded the maximum daily dose.
1 year study
(measured
total number
of changes
over
1 year)
BZ = benzodiazepine, Sig = statistically significant (p < 0.05), GP = General Practitioner
Smith and Tett BMC Health Services Research 2010, 10:321
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Page 7 of 12and expensive approach of educational sessions or GP
consultations.
Educational and support group sessions were also
used as an educational method. The studies using group
sessions did see larger reductions (69% and 59% dose
reduction [27,28] respectively) in benzodiazepine use
compared to the mail-out studies but neither of these
studies used a control group so conclusions are difficult
to draw.
Targeted at GPs
Education for GPs included packages containing benzo-
diazepine prescribing guidelines, face to face visits and
‘promotional’ material with key messages.
When compared to control, 50% of the educational
interventions targeted at GPs had significant decreased
benzodiazepine use and 17% (1 study, [29]) which did
not reduce overall use of benzodiazepines did signifi-
cantly decrease the number of new patients being pre-
scribed benzodiazepines.
The study [30] that saw the largest reduction in
benzodiazepine use differed from the other GP targeted
educational studies as it did not rely upon voluntary parti-
cipation. Any GP who prescribed to a Washington State
Medicaid beneficiary deemed to be a “high utilizer” of ben-
zodiazepines was sent the intervention package (see Table
1 for further details). In the other studies the voluntary
recruitment design may have resulted in the participation
of GPs who prescribed benzodiazepines more rationally
(pre-intervention) than non-participating GPs. If this
occurred, smaller changes between intervention (pre and
post) and control groups would be seen, and this selection
bias could be influencing the conclusions.
Differences in the delivery of the education (mail vs.
personal visit) had varying effects on the “success” of
the studies. For example, Smith et al, 1998 (the study
with the largest decrease in benzodiazepine use) deliv-
ered education via mail-out. This success is supported
by a study which had a mail-out and educational visit
Studies for full text analysis: 55
Studies retrieved: 8438 
Studies excluded based 
on title: 8073
Studies for more in depth 
evaluation: 365
Studies excluded based on abstract: 315 
Educational 
Interventions: 19
Audit and Feedback 
interventions: 10
Studies  excluded after full text analysis: 
23
Studies which met inclusion criteria 
and  included in the review: 32*
Alert Interventions:2 
* 1 study was multi-faceted 
Figure 1 Flow Chart of studies retrieved and included in the review.
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Page 8 of 12intervention arms [31]. They found a significant differ-
ence in the decrease of benzodiazepine use between
control and both the educational visit (24%) and the
mail out (14%) arms and between the two interventions.
However Holm,1990 found no significant difference
between the education visit and the mail-out arms of
their intervention [32].
Targeted at long term care facilities
The educational tools used in long term care facilities
varied from prescribing algorithms and bulletins to staff
meetings and lectures.
Educational interventions delivered to long term care
facilities differed compared to those delivered to GPs
and consumers in two ways. Firstly, some studies
included audit and feedback in addition to education
[33-35] and all of the studies were multi faceted (the
education was directed at a variety of people, including
nurses, GPs, family members, pharmacists) rather than
just targeting GPs. This multifaceted approach could in
some part be responsible for the larger percentage of
studies which either decreased use or reported improved
prescribing of benzodiazepine in this setting when com-
pared to the GP targeted studies.
The majority of the long term care facility educational
studies used pharmacists to deliver the “educational
message” to staff, (one study did not specify [34] and 1
used a psychologist [36]). Of the 5 pharmacist led stu-
dies two were unsuccessful in either decreasing benzo-
diazepine use or increasing appropriate prescribing
suggesting that, in this context, the type of health pro-
fessional delivering the education does not determine
the success of the intervention.
Audit and feedback
The audit and feedback studies which targeted long
term care facilities involved more than 1 health profes-
sional e.g. doctors, nurses, physiotherapists and pharma-
cists whereas the GP targeted interventions only
involved the GPs. This may be responsible for the differ-
ence in results between the 2 groups, as the audit and
feedback studies in long term care facilities all improved
appropriateness of prescribing (as defined by each
study) but only 1 of the 3 GP studies achieved this same
success. Audit and feedback may be resisted by some
prescribers, which may explain perhaps why better
results for benzodiazepine prescribing were obtained in
long term care facility audits, where multiple different
health practitioners were targeted compared to the
audits of individual GPs alone.
Another factor that appears to affect the outcome of
the interventions is how the feedback was delivered. All
studies which successfully achieved their aim (reducing
or improving use of benzodiazepines) gave feedback
orally, either in a meeting or individual consultations
instead of just mailing.
Both success and failure to improve benzodiazepine
prescribing was seen in both the audit and feedback
i n t e r v e n t i o ng r o u p[ 3 7 - 3 9 ]a n dt h ea u d i ta n df e e d b a c k
in conjunction with education group [33-35,40]. It can
therefore not be determined if education in addition to
audit and feedback interventions improves the outcome
of the study.
Alerts
The GP targeted decision support tool alerted GPs when
they were either prescribing a long acting benzodiaze-
pine to a patient over 65 or initiating a patient on a
benzodiazepine. This intervention found no difference
between intervention and control when measuring the
change in the target medications per 10,000 patients per
quarter. This is not surprising as GPs are renowned for
turning the electronic reminders/alerts off or ignoring
all alerts that appear [41].
The second alert system was run through the phar-
macy, where the pharmacist contacted the GP to discuss
the prescription if an alert appeared. This study did see
a significant increase in the appropriate prescribing of
benzodiazepines (as determined by an independent advi-
sory board and the use of Beers Criteria) [20]. An
improvement was defined as a decrease in number of
benzodiazepine prescriptionsw h i c h ,a )e x c e e d e dt h e r a -
peutic dose, b) prescribed to the over 65 s and c) con-
tained long acting benzodiazepines.
With both studies having a similar definition of
“appropriate”,t h ed i f f e r e n c eh e r ea p p e a r st ob et h e
pharmacist involvement. It has been suggested that
community pharmacists are an underused resources in
prescribing studies [42], therefore it may be an appropri-
ate time to incorporate pharmacists into future studies,
as they are fast becoming one of the most utilized health
professionals in many countries [43].
Discussion
Summary of Evidence
This investigation solely focuses on interventions designed
to improve prescribing and/or use of benzodiazepines and
related drugs in the last 20 years and has demonstrated
that many different interventions strategies are used
worldwide, with varying success. The most successful
interventions to improve prescribing and use of benzodia-
zepines were those which are multi-faceted, targeting a
number of groups (prescribers as well as consumers).
Limitations
This study may be limited by the fact that this was not a
complete systematic review and there are insufficient
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Page 9 of 12data available to conduct a meta-analysis on the effect
size of any specific intervention, hence bias in interpreta-
tion may have been introduced by the non-quantitative
summary techniques.
Knowledge Translation
The points below outline some aspects of the study
designs that may enhance the success of any future
intervention.
Points which appear to enhance success of an
intervention
￿ Advise individual patients to stop/cut back on their
benzodiazepines (either via letter or face-to-face).
A follow-up consultation may improve the success
for individual patients.
￿ Encourage consumer support groups, to enhance
self-withdrawal of benzodiazepines by patients
￿ Encourage inter-professional approach e.g.
pharmacists alerting prescribers of potentially inap-
propriate prescribing of benzodiazepines or nurses reg-
ularly contacting/providing information to patients
who are trying to cut back on their benzodiazepines
￿ Use oral feedback rather than written in audit and
feedback studies to GPs; consider group audit, such
as through long term care facilities, rather than audit
of individuals
￿ Educate all long term care staff about alternative
methods to treat insomnia and cutting back on the
use of benzodiazepines
Conclusions
One of the key success factors noted with all intervention
approaches was the use of a multi-target design where a
number of audiences or approaches were used; this may
be why the consumer interventions worked well, as
essentially they had two target audiences, the consumer
and the GP or health professional involved in the study.
This also agrees with findings from other therapeutic
areas, for example a mass media campaign around appro-
priate use of antimicrobials and student taught programs
for reducing antibiotic use during colds or flu [9,44,45].
The one distinctly multi-faceted study in this review of
benzodiazepine interventions also saw a sustained reduc-
tion (19%) in benzodiazepine use when all health profes-
sionals and the community were educated [24].
Conducting multi-faceted interventions can often be
labor intensive, expensive and difficult to administer on a
large scale basis and therefore can usually only be main-
tained for a limited time. Future interventions which use
delivery methods such as email or websites may help to
ameliorate some of these financial or ‘reach’ problems.
This commentary has suggested that the use of support/
educational groups for consumers may improve the ‘suc-
cess’ of an intervention, this could easily be administered
using social networking technologies.
Whilst it is known that many healthcare providers
have resisted using information technology due to priv-
acy and infrastructure issues [46,47], many pharmacies,
and medical centres now use the internet and email reg-
ularly and frequently [48-50]. Future investigation and
validation into the effectiveness of electronic delivery
method to a number of target groups could be benefi-
cial, as varying results have been seen [51-54]. Studies
which incorporate newer information technology may
lead to more sustained changes as they are simple to
administer, and can have a large scale impact by inex-
pensively involving a variety of health professionals and/
or consumers [55,56].
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